• This is the first release of 36-week symptom response & tissue health data for the highest dose (Cohort 9) from the dose escalation portion of Eupraxia's RESOLVE trial. 
     
  • At 36 weeks, patients in Cohort 9 (n=3) demonstrated a robust response in both tissue health and symptom response compared to their baseline levels.
     
  • Patients in Cohort 9 also demonstrated the highest response in tissue health at week 36 compared to all other dose cohorts in the RESOLVE trial.
     
  • Clinical remission in symptoms was maintained in 66% of the patients (2 of 3) in Cohort 9 at week 36. This level of remission was first achieved at week 8 and was maintained through 36 weeks.
     
  • EP-104GI continues to be well tolerated by patients receiving the drug; 31 patients have been treated in the Phase 1b/2a study and over 230 patient-months of follow-up have been reported with no drug related Serious Adverse Events ("SAEs"). There still have been no cases of oropharyngeal candidiasis, a commonly reported adverse event with the oral delivery of steroids.
     

VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced 36-week tissue health and symptom data from patients in the highest dose cohort from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis ("EoE").